Chlorthalidone 25 mg recall expands to 13,567 bottles as FDA warns of dissolution testing failure

Drugmaker Inventia Healthcare initiated a nationwide voluntary recall of 13,567 bottles of the blood pressure treatment chlorthalidone after samples failed quality specifications. Laboratory evaluations revealed that the 25-milligram tablets do not dissolve within established time standards, a defect that can prevent the body from absorbing the active ingredient and undermine hypertension control.
The corrective action targets 100-count bottles circulated across the United States supply chain. Regulators identified the issue during dissolution profiling, which demonstrated that the pills disintegrate too slowly to guarantee appropriate therapeutic delivery. Medical specialists advise patients using the medication to check their prescription labels while continuing their regimen under clinical supervision.
The United States Food and Drug Administration assigned a Class II designation to the market withdrawal on September 17, 2026. Under agency definitions, this classification applies to situations where exposure to a noncompliant product may trigger temporary or medically reversible health issues, while the risk of severe adverse outcomes remains remote.
Affected lot details and regulatory registry numbers
- Product: Chlorthalidone tablets USP 25 mg in 100-count bottles
- Affected lot number: RISA24002
- National Drug Code: 64980-599-01
- Expiration date: April 2027
- FDA enforcement database entry: D-0852-2026
Nationwide distribution and previous manufacturing actions
Manufactured in India by Inventia Healthcare Limited, the diuretic is marketed and supplied across the American market by Rising Pharma Holdings Inc., based in East Brunswick, New Jersey. The pharmaceutical firm formally initiated the voluntary recall on September 3, 2026, following internal and regulatory testing evaluations. This latest withdrawal pushes the total volume of chlorthalidone recalled by the company past 25,000 bottles in 2026, adding to an earlier batch of 11,460 bottles pulled in June due to similar disintegration problems.
Read also: FDA discute uso de testosterona em mulheres na menopausa em meio a desafios de acesso e dosagem
Clinical guidance regarding hypertension treatment regimens
Cardiologists and public health agencies warn that individuals taking tablets from the flagged lot must avoid stopping their prescriptions abruptly. Chlorthalidone is widely prescribed to manage chronic hypertension and treat fluid buildup related to cardiac, liver, and kidney conditions, meaning an unmonitored cessation could trigger dangerous blood pressure spikes or cardiovascular events. Patients who verify that their medication belongs to the recalled batch should consult their prescribing physician or dispensing pharmacist to arrange an effective alternative therapy.
Keep reading: FDA classifies recall of six hand soaps across 15 states
Inventia Healthcare did not issue public statements or reply to media requests for comment prior to the release of the agency enforcement records. Retailers and distribution facilities holding the affected inventory have been instructed to halt sales and process returns through standard pharmaceutical recovery channels.







